Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

Published:2009-09-30 Issue:1 Volume:3 Page:49-56
ISSN:1933-0219
Container-title:Mucosal Immunology
language:en
Short-container-title:Mucosal Immunol

Author:

Vandenbroucke K,de Haard H,Beirnaert E,Dreier T,Lauwereys M,Huyck L,Van Huysse J,Demetter P,Steidler L,Remaut E,Cuvelier C,Rottiers P

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/mi2009116.pdf

Reference46 articles.

1. Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521–533 (2003).

2. Papadakis, K.A. & Targan, S.R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119, 1148–1157 (2000).

3. Vassalli, P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10, 411–452 (1992).

4. van Dullemen, H.M. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129–135 (1995).

5. Hanauer, S.B. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541–1549 (2002).

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetically engineered bacteria as inflammatory bowel disease therapeutics;Engineering Microbiology;2024-12

2. Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases;Drug Discovery Today;2024-08

3. Single-Domain Antibodies—Novel Tools to Study and Treat Allergies;International Journal of Molecular Sciences;2024-07-11

4. Therapeutic manipulation of the microbiome in liver disease;Hepatology;2024-06-26

5. Engineering bacterial warriors: harnessing microbes to modulate animal physiology;Current Opinion in Biotechnology;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3